Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Molecular and Cellular Biology, Genetics

Abstract 93: Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US

Lola Rahib, Anitra Engebretson, Michael J. Pishvaian, Jonathan R. Brody, William A. Hoos, Emily E. Lyons, Joseph Bender, Emanuel F. Petricoin, Subha Madhavan, Craig Heartwell and Lynn M. Matrisian
Lola Rahib
Pancreatic Cancer Action Network, Manhattan Beach, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anitra Engebretson
Pancreatic Cancer Action Network, Manhattan Beach, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Pishvaian
Personalized Cancer Therapy Inc (dba Perthera), McLean, VA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan R. Brody
Personalized Cancer Therapy Inc (dba Perthera), McLean, VA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Hoos
Pancreatic Cancer Action Network, Manhattan Beach, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily E. Lyons
Pancreatic Cancer Action Network, Manhattan Beach, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Bender
Personalized Cancer Therapy Inc (dba Perthera), McLean, VA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emanuel F. Petricoin
Personalized Cancer Therapy Inc (dba Perthera), McLean, VA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Subha Madhavan
Personalized Cancer Therapy Inc (dba Perthera), McLean, VA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Heartwell
Personalized Cancer Therapy Inc (dba Perthera), McLean, VA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn M. Matrisian
Pancreatic Cancer Action Network, Manhattan Beach, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2016-93 Published July 2016
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA

Abstract

Commercial genomic and protein-based profiling was performed on tissue from pancreatic cancer patients who enrolled in the Pancreatic Cancer Action Network's Know Your Tumor (KYT) service. The service offers molecular profiling for patients with resectable or metastatic disease, in preparation for their next treatment plan. Patients are eligible to enroll at any institution, clinic, or cancer center in the US. Biopsies, tissue retrieval and testing is coordinated by Perthera, Inc.

From 6/2014 to 11/2015 tumor biopsies, resected or archived tissue was obtained from 152 (53% male) pancreatic cancer patients and profiling including NGS/FISH (144 patients) and IHC (143 patients) was performed. The median age at biopsy or resection was 63 (25-83), 55% of the tissue came from liver, 16% from pancreas, 7% lung, 4% peritoneum, and 18% from another type of tissue. 87% of the patients were diagnosed with pancreatic ductal adenocarcinoma and the remaining with another form of confirmed or suspected pancreatic cancer.

The most identified pathogenic mutations were KRAS (85%), TP53 (72%), CDKN2A (47%), CDKN2B (24%), SMAD4 (22%), ARID1A (10%), STK11 (7%), and BRCA2 (5%). The average number of genomic alterations (likely but not confirmed to be somatic) detected was five per patient from a panel of 320 genes. Molecular modifications that are linked to a treatment option were observed in 44% of patients. Twenty four of 144 patients (17%) had mutations in at least one DNA repair gene potentially benefiting from platinum or PARP inhibitor-based therapies, including BRCA2 (5%), ATM (4%), BAP1 (4%), SMARCA4 (3%), FANC (1%), CHEK2 (1%), and PALB2 (<1%). Other actionable molecular phenotypes observed include anti-HER2 therapies targeting ERBB2 amplifications (3%) and mTOR inhibitors suitable for patients with mutations in STK11/LKB1 (7%), PTEN (3.5%), PIK3R1 (<1%), or PIK3CA (3%). Actionable alterations identified with a low frequency (<2%) include RET fusions, amplifications of FGFR, CRKL, AXL, and mutations in NTRK3, MEN1 (PNET), and BRAF. One patient harbored the BRAF V600E mutation, prompting consideration of off label melanoma-approved therapy. Overexpression of ALK by IHC was observed in one patient who chose to enroll in a ceritinib clinical trial. Six percent of patients were PDL-1 positive, and 22% were positive for PD-1 from tumor infiltrating lymphocytes, suggesting possible activity from immune checkpoint inhibitors.

To date, 7 of the 152 patients have enrolled in a clinical trial, 4 were treated with an off label treatment, 67 have yet to make their next treatment decision, and 53 are known to be deceased. KYT has successfully profiled tumors and presented targeted treatment options to patients and physicians in 33 states regardless of a patient's socioeconomic background and geographic location, moving the field a step closer towards a democratized, personalized approach to treating pancreatic cancer.

Citation Format: Lola Rahib, Anitra Engebretson, Michael J. Pishvaian, Jonathan R. Brody, William A. Hoos, Emily E. Lyons, Joseph Bender, Emanuel F. Petricoin, Subha Madhavan, Craig Heartwell, Lynn M. Matrisian. Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 93.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 76 (14 Supplement)
July 2016
Volume 76, Issue 14 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 93: Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 93: Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US
Lola Rahib, Anitra Engebretson, Michael J. Pishvaian, Jonathan R. Brody, William A. Hoos, Emily E. Lyons, Joseph Bender, Emanuel F. Petricoin, Subha Madhavan, Craig Heartwell and Lynn M. Matrisian
Cancer Res July 15 2016 (76) (14 Supplement) 93; DOI: 10.1158/1538-7445.AM2016-93

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 93: Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US
Lola Rahib, Anitra Engebretson, Michael J. Pishvaian, Jonathan R. Brody, William A. Hoos, Emily E. Lyons, Joseph Bender, Emanuel F. Petricoin, Subha Madhavan, Craig Heartwell and Lynn M. Matrisian
Cancer Res July 15 2016 (76) (14 Supplement) 93; DOI: 10.1158/1538-7445.AM2016-93
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology, Genetics

  • Abstract LB-323: Comparative miRNA microarray profiling indicates miR-363 promotes chemoresistance in ovarian cancer cells by targeting the Hippo member, LATS2
  • Abstract LB-268: Rate of temporal citrate efflux from malignant mitochondria predicts clinical aggressiveness in breast tumors
  • Abstract LB-324: Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness via targeting GRB7
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-328: Mir-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44
  • Abstract LB-331: Advanced DNA-gold nanoprobe-based direct and sensitive quantification of novel microRNAs in prostate cancer
  • Abstract LB-336: Specific serine phosphorylation of IRE-1 controls enhanced splicing of XBP-1 and regulated IRE-1-dependent decay (RIDD)
Show more 3

Poster Presentations - Genomic Analysis of Cancers

  • Abstract 90: A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia
  • Abstract 94: Genomic landscape and clonal expansions of upper urinary tract urothelial carcinoma
  • Abstract 104: Investigation of genetic architecture of multiple myeloma by next generation sequencing
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement